New research: High burden of hepatitis C among people who inject drugs

July 23, 2018, University of New South Wales
New research: High burden of hepatitis C among people who inject drugs
This the estimated prevalence of HCV viraemic infection among current PWID, by country. Credit: NDARC

New research: High burden of hepatitis C among people who inject drugs highlights the urgent need for harm reduction and treatment strategies

Globally, more than one in three (39%) people who have injected drugs in the last year are living with C infection, according to new research from the National Drug and Alcohol Research Centre and the Kirby Institute at UNSW Sydney.

The research, published today in Addiction, is the first time researchers have estimated the global, regional and national numbers of people who inject drugs that are living with hepatitis C. This work will set the baseline for tracking progress of strategies designed to prevent and treat hepatitis C among people who inject drugs.

"The availability of simple hepatitis C therapies with cure rates greater than 90%, is one of the most exciting advances in medicine in recent decades," said Associate Professor Jason Grebely from the Kirby Institute, and lead author on the study. "Importantly, recent research from the Kirby Institute has shown that these therapies are very effective at curing hepatitis C among people who have recently injected drugs. We need to expand hepatitis C prevention, testing and treatment strategies among people who inject drugs in order to achieve global hepatitis C elimination."

In Australia, there are almost 40,000 people who have recently injected drugs living with hepatitis C. However, Australia is one of only four countries worldwide with high coverage of both needle and syringe programs and opioid substitution therapies. "Australia has been an international leader in its response to hepatitis C," said Associate Professor Grebely. "The fact that hepatitis C treatments are available for all individuals without restrictions based on current or previous drug use means we are likely to achieve the World Health Organisation goal to eliminate hepatitis as a major by 2030, including among people who inject drugs."

According to the new research, among the 71 million people living with hepatitis C globally, 6.1 million people have recently injected drugs. While this only represents 8.5% of all infections, there is a considerable further burden among people with a history of injecting drug use. It is estimated that 25% of all new hepatitis C infections occur among people who inject drugs, as a result of sharing needles and syringes. As such, people who inject drugs are a priority population for hepatitis C elimination efforts.

"Globally, access to harm reduction is poor, with only 1% of people who inject drugs living in countries where needle and syringe programs and opioid substitution therapy are widely available," said Dr. Sarah Larney from the National Drug & Alcohol Research Centre, co-author of the study. "We know these harm reduction strategies are effective in preventing hepatitis C. We must improve our efforts to enhance strategies to prevent hepatitis C infection and reduce the number of new infections."

The new research reveals that the greatest numbers of people with hepatitis C who have recently injected drugs live in Eastern Europe, East and Southeast Asia, and North America. Globally, half of all people with hepatitis C who have recently injected drugs live in four countries: the Russian Federation, the United States, China, and Brazil.

Judy Chang, Executive Director of the International Network of People Who Use Drugs, said, "it is concerning that over half of all hepatitis C infections among people who have recently injected drugs occur in countries with inadequate coverage of harm reduction services. The global elimination of hepatitis C as a public health threat will not be achievable unless we improve access to harm reduction services, de-stigmatise drug use and users, and improve the overall health of people who use drugs."

Explore further: Hepatitis C vaccine could dramatically reduce transmission in people who inject drugs

More information: Jason Grebely et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs, Addiction (2018). DOI: 10.1111/add.14393

Related Stories

Hepatitis C vaccine could dramatically reduce transmission in people who inject drugs

July 11, 2018
Among the most serious consequences of the opioid epidemic is the spread of hepatitis C among injecting drug users.

People who use drugs require prioritization, not exclusion, in HCV elimination

September 6, 2017
An international conference bringing together hepatitis C experts from around the world is today calling for strategies to prioritise people who use drugs, saying hepatitis C elimination is impossible without them.

New perspectives on risk of HIV and hepatitis among injecting drug users

October 24, 2017
Reviews of the global prevalence of injecting drug use and of interventions to prevent the spread of blood-borne viruses among people who inject drugs paint a worrying picture.

Latest research shows Australia on track to cure hepatitis C

February 21, 2017
More Australians have been treated for hepatitis C in the past 12 months than the last decade combined, following the listing of a new generation therapy on the Pharmaceutical Benefits Scheme.

Hepatitis C 'treatment as prevention' strategy examined in new study

November 30, 2017
Hepatitis C infection is a global phenomenon that affects millions worldwide, with an estimated 30,500 new cases in the United States alone each year. Expanding treatment, however, could go a long way toward preventing transmission ...

Interventions for reducing hepatitis C infection in people who inject drugs

September 26, 2017
The first global review to quantify the impact of needle syringe programmes (NSP) and opioid substitution treatment (OST) in reducing the risk of becoming infected with the hepatitis C virus is published in Cochrane Library ...

Recommended for you

Tibetan sheep highly susceptible to human plague, originates from marmots

August 16, 2018
In the Qinghai-Tibet plateau, one of the region's highest risk areas for human plague, Himalayan marmots are the primary carriers of the infectious bacterium Y. pestis. Y. pestis infection can be transmitted to humans and ...

Autoimmunity plays role in development of COPD, study finds

August 16, 2018
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information ...

Scientists identify nearly 200 potential tuberculosis drug targets

August 16, 2018
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost ...

Reliable point-of-care blood test can help prevent toxoplasmosis

August 16, 2018
A recent study, performed in Chicago and Rabat, Morocco, found that a novel finger-prick test for infection with the parasite Toxoplasma gondii during pregnancy—and many other potential applications—is 100 percent sensitive ...

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.